

Global Gene Therapy for Neurodegenerative Diseases Supply, Demand and Key Producers, 2023-2029

https://marketpublishers.com/r/GC4760E854B7EN.html

Date: September 2023

Pages: 109

Price: US\$ 4,480.00 (Single User License)

ID: GC4760E854B7EN

Abstracts

The global Gene Therapy for Neurodegenerative Diseases market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

This report studies the global Gene Therapy for Neurodegenerative Diseases demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Gene Therapy for Neurodegenerative Diseases, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Gene Therapy for Neurodegenerative Diseases that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Gene Therapy for Neurodegenerative Diseases total market, 2018-2029, (USD Million)

Global Gene Therapy for Neurodegenerative Diseases total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Gene Therapy for Neurodegenerative Diseases total market, key domestic companies and share, (USD Million)

Global Gene Therapy for Neurodegenerative Diseases revenue by player and market



share 2018-2023, (USD Million)

Global Gene Therapy for Neurodegenerative Diseases total market by Type, CAGR, 2018-2029, (USD Million)

Global Gene Therapy for Neurodegenerative Diseases total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Gene Therapy for Neurodegenerative Diseases market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Voyager Therapeutics, Uniqure N.V., Axovant Gene Therapies, Novartis Ag, Amicus Therapeutics, Regenxbio Inc., Sarepta Therapeutics, Gensight Biologics and Krystal Biotech, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Gene Therapy for Neurodegenerative Diseases market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Gene Therapy for Neurodegenerative Diseases Market, By Region:

United States
China
Europe
Japan

South Korea







market?

Novartis Ag	
Amicus Therapeutics	
Regenxbio Inc.	
Sarepta Therapeutics	
Gensight Biologics	
Krystal Biotech	
Avexis	
Key Questions Answered	
1. How big is the global Gene Therapy for Neurodegenerative Diseases market?	

3. What is the year over year growth of the global Gene Therapy for Neurodegenerative Diseases market?

2. What is the demand of the global Gene Therapy for Neurodegenerative Diseases

- 4. What is the total value of the global Gene Therapy for Neurodegenerative Diseases market?
- 5. Who are the major players in the global Gene Therapy for Neurodegenerative Diseases market?



Contents

1 SUPPLY SUMMARY

- 1.1 Gene Therapy for Neurodegenerative Diseases Introduction
- 1.2 World Gene Therapy for Neurodegenerative Diseases Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Gene Therapy for Neurodegenerative Diseases Total Market by Region (by Headquarter Location)
- 1.3.1 World Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2029), (by Headquarter Location)
- 1.3.2 United States Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
 - 1.3.3 China Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
 - 1.3.4 Europe Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
 - 1.3.5 Japan Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
- 1.3.6 South Korea Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
- 1.3.7 ASEAN Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
- 1.3.8 India Gene Therapy for Neurodegenerative Diseases Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
- 1.4.1 Gene Therapy for Neurodegenerative Diseases Market Drivers
- 1.4.2 Factors Affecting Demand
- 1.4.3 Gene Therapy for Neurodegenerative Diseases Major Market Trends

2 DEMAND SUMMARY

- 2.1 World Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
- 2.2 World Gene Therapy for Neurodegenerative Diseases Consumption Value by Region
- 2.2.1 World Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2018-2023)
- 2.2.2 World Gene Therapy for Neurodegenerative Diseases Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
- 2.4 China Gene Therapy for Neurodegenerative Diseases Consumption Value



(2018-2029)

- 2.5 Europe Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
- 2.6 Japan Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
- 2.7 South Korea Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
- 2.8 ASEAN Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)
- 2.9 India Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029)

3 WORLD GENE THERAPY FOR NEURODEGENERATIVE DISEASES COMPANIES COMPETITIVE ANALYSIS

- 3.1 World Gene Therapy for Neurodegenerative Diseases Revenue by Player (2018-2023)
- 3.2 Industry Rank and Concentration Rate (CR)
- 3.2.1 Global Gene Therapy for Neurodegenerative Diseases Industry Rank of Major Players
- 3.2.2 Global Concentration Ratios (CR4) for Gene Therapy for Neurodegenerative Diseases in 2022
- 3.2.3 Global Concentration Ratios (CR8) for Gene Therapy for Neurodegenerative Diseases in 2022
- 3.3 Gene Therapy for Neurodegenerative Diseases Company Evaluation Quadrant
- 3.4 Gene Therapy for Neurodegenerative Diseases Market: Overall Company Footprint Analysis
 - 3.4.1 Gene Therapy for Neurodegenerative Diseases Market: Region Footprint
- 3.4.2 Gene Therapy for Neurodegenerative Diseases Market: Company Product Type Footprint
- 3.4.3 Gene Therapy for Neurodegenerative Diseases Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER



LOCATION)

- 4.1 United States VS China: Gene Therapy for Neurodegenerative Diseases Revenue Comparison (by Headquarter Location)
- 4.1.1 United States VS China: Gene Therapy for Neurodegenerative Diseases Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
- 4.1.2 United States VS China: Gene Therapy for Neurodegenerative Diseases Revenue Market Share Comparison (2018 & 2022 & 2029)
- 4.2 United States Based Companies VS China Based Companies: Gene Therapy for Neurodegenerative Diseases Consumption Value Comparison
- 4.2.1 United States VS China: Gene Therapy for Neurodegenerative Diseases Consumption Value Comparison (2018 & 2022 & 2029)
- 4.2.2 United States VS China: Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based Gene Therapy for Neurodegenerative Diseases Companies and Market Share, 2018-2023
- 4.3.1 United States Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (States, Country)
- 4.3.2 United States Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023)
- 4.4 China Based Companies Gene Therapy for Neurodegenerative Diseases Revenue and Market Share, 2018-2023
- 4.4.1 China Based Gene Therapy for Neurodegenerative Diseases Companies, Company Headquarters (Province, Country)
- 4.4.2 China Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023)
- 4.5 Rest of World Based Gene Therapy for Neurodegenerative Diseases Companies and Market Share, 2018-2023
- 4.5.1 Rest of World Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (States, Country)
- 4.5.2 Rest of World Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023)

5 MARKET ANALYSIS BY TYPE

- 5.1 World Gene Therapy for Neurodegenerative Diseases Market Size Overview by Type: 2018 VS 2022 VS 2029
- 5.2 Segment Introduction by Type
- 5.2.1 Gene Replacement Therapy



- 5.2.2 Gene Silencing Therapy
- 5.2.3 Gene Editing Therapy
- 5.2.4 Enzyme Replacement Therapy
- 5.3 Market Segment by Type
- 5.3.1 World Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
- 5.3.2 World Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2029)
- 5.3.3 World Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2029)

6 MARKET ANALYSIS BY APPLICATION

- 6.1 World Gene Therapy for Neurodegenerative Diseases Market Size Overview by Application: 2018 VS 2022 VS 2029
- 6.2 Segment Introduction by Application
 - 6.2.1 Hospitals and Clinics
 - 6.2.2 Research Institutions
 - 6.2.3 Biotechnology Companies
 - 6.2.4 Others
 - 6.2.5 Others
- 6.3 Market Segment by Application
- 6.3.1 World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
- 6.3.2 World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2029)
- 6.3.3 World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2029)

7 COMPANY PROFILES

- 7.1 Voyager Therapeutics
 - 7.1.1 Voyager Therapeutics Details
 - 7.1.2 Voyager Therapeutics Major Business
- 7.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
- 7.1.4 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
 - 7.1.5 Voyager Therapeutics Recent Developments/Updates



- 7.1.6 Voyager Therapeutics Competitive Strengths & Weaknesses
- 7.2 Uniqure N.V.
 - 7.2.1 Uniqure N.V. Details
 - 7.2.2 Uniqure N.V. Major Business
- 7.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product and Services
- 7.2.4 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
 - 7.2.5 Uniqure N.V. Recent Developments/Updates
 - 7.2.6 Uniqure N.V. Competitive Strengths & Weaknesses
- 7.3 Axovant Gene Therapies
 - 7.3.1 Axovant Gene Therapies Details
 - 7.3.2 Axovant Gene Therapies Major Business
- 7.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product and Services
- 7.3.4 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
 - 7.3.5 Axovant Gene Therapies Recent Developments/Updates
- 7.3.6 Axovant Gene Therapies Competitive Strengths & Weaknesses
- 7.4 Novartis Ag
 - 7.4.1 Novartis Ag Details
 - 7.4.2 Novartis Ag Major Business
- 7.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Product and Services
- 7.4.4 Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
 - 7.4.5 Novartis Ag Recent Developments/Updates
 - 7.4.6 Novartis Ag Competitive Strengths & Weaknesses
- 7.5 Amicus Therapeutics
 - 7.5.1 Amicus Therapeutics Details
 - 7.5.2 Amicus Therapeutics Major Business
- 7.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
- 7.5.4 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
 - 7.5.5 Amicus Therapeutics Recent Developments/Updates
 - 7.5.6 Amicus Therapeutics Competitive Strengths & Weaknesses
- 7.6 Regenxbio Inc.
- 7.6.1 Regenxbio Inc. Details



- 7.6.2 Regenxbio Inc. Major Business
- 7.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product and Services
- 7.6.4 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
 - 7.6.5 Regenxbio Inc. Recent Developments/Updates
 - 7.6.6 Regenxbio Inc. Competitive Strengths & Weaknesses
- 7.7 Sarepta Therapeutics
 - 7.7.1 Sarepta Therapeutics Details
 - 7.7.2 Sarepta Therapeutics Major Business
- 7.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
- 7.7.4 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
 - 7.7.5 Sarepta Therapeutics Recent Developments/Updates
- 7.7.6 Sarepta Therapeutics Competitive Strengths & Weaknesses
- 7.8 Gensight Biologics
 - 7.8.1 Gensight Biologics Details
 - 7.8.2 Gensight Biologics Major Business
- 7.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product and Services
- 7.8.4 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
 - 7.8.5 Gensight Biologics Recent Developments/Updates
 - 7.8.6 Gensight Biologics Competitive Strengths & Weaknesses
- 7.9 Krystal Biotech
 - 7.9.1 Krystal Biotech Details
 - 7.9.2 Krystal Biotech Major Business
- 7.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product and Services
- 7.9.4 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023)
 - 7.9.5 Krystal Biotech Recent Developments/Updates
 - 7.9.6 Krystal Biotech Competitive Strengths & Weaknesses
- 7.10 Avexis
 - 7.10.1 Avexis Details
 - 7.10.2 Avexis Major Business
- 7.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Product and Services
- 7.10.4 Avexis Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin



and Market Share (2018-2023)

- 7.10.5 Avexis Recent Developments/Updates
- 7.10.6 Avexis Competitive Strengths & Weaknesses

8 INDUSTRY CHAIN ANALYSIS

- 8.1 Gene Therapy for Neurodegenerative Diseases Industry Chain
- 8.2 Gene Therapy for Neurodegenerative Diseases Upstream Analysis
- 8.3 Gene Therapy for Neurodegenerative Diseases Midstream Analysis
- 8.4 Gene Therapy for Neurodegenerative Diseases Downstream Analysis

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

- 10.1 Methodology
- 10.2 Research Process and Data Source
- 10.3 Disclaimer



List Of Tables

LIST OF TABLES

Table 1. World Gene Therapy for Neurodegenerative Diseases Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World Gene Therapy for Neurodegenerative Diseases Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World Gene Therapy for Neurodegenerative Diseases Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Gene Therapy for Neurodegenerative Diseases Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World Gene Therapy for Neurodegenerative Diseases Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World Gene Therapy for Neurodegenerative Diseases Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World Gene Therapy for Neurodegenerative Diseases Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key Gene Therapy for Neurodegenerative Diseases Players in 2022

Table 12. World Gene Therapy for Neurodegenerative Diseases Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global Gene Therapy for Neurodegenerative Diseases Company Evaluation Quadrant

Table 14. Head Office of Key Gene Therapy for Neurodegenerative Diseases Player

Table 15. Gene Therapy for Neurodegenerative Diseases Market: Company Product Type Footprint

Table 16. Gene Therapy for Neurodegenerative Diseases Market: Company Product Application Footprint

Table 17. Gene Therapy for Neurodegenerative Diseases Mergers & Acquisitions Activity

Table 18. United States VS China Gene Therapy for Neurodegenerative Diseases Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China Gene Therapy for Neurodegenerative Diseases



Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (States, Country)

Table 21. United States Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Gene Therapy for Neurodegenerative Diseases Revenue Market Share (2018-2023)

Table 23. China Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (Province, Country)

Table 24. China Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Gene Therapy for Neurodegenerative Diseases Revenue Market Share (2018-2023)

Table 26. Rest of World Based Gene Therapy for Neurodegenerative Diseases Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Gene Therapy for Neurodegenerative Diseases Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Gene Therapy for Neurodegenerative Diseases Revenue Market Share (2018-2023)

Table 29. World Gene Therapy for Neurodegenerative Diseases Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (USD Million)

Table 31. World Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2029) & (USD Million)

Table 32. World Gene Therapy for Neurodegenerative Diseases Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (USD Million)

Table 34. World Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2029) & (USD Million)

Table 35. Voyager Therapeutics Basic Information, Area Served and Competitors

Table 36. Voyager Therapeutics Major Business

Table 37. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services

Table 38. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases

Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. Voyager Therapeutics Recent Developments/Updates

Table 40. Voyager Therapeutics Competitive Strengths & Weaknesses



- Table 41. Uniqure N.V. Basic Information, Area Served and Competitors
- Table 42. Uniqure N.V. Major Business
- Table 43. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product and Services
- Table 44. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 45. Uniqure N.V. Recent Developments/Updates
- Table 46. Uniqure N.V. Competitive Strengths & Weaknesses
- Table 47. Axovant Gene Therapies Basic Information, Area Served and Competitors
- Table 48. Axovant Gene Therapies Major Business
- Table 49. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product and Services
- Table 50. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases
- Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 51. Axovant Gene Therapies Recent Developments/Updates
- Table 52. Axovant Gene Therapies Competitive Strengths & Weaknesses
- Table 53. Novartis Ag Basic Information, Area Served and Competitors
- Table 54. Novartis Ag Major Business
- Table 55. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product and Services
- Table 56. Novartis Ag Gene Therapy for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 57. Novartis Ag Recent Developments/Updates
- Table 58. Novartis Ag Competitive Strengths & Weaknesses
- Table 59. Amicus Therapeutics Basic Information, Area Served and Competitors
- Table 60. Amicus Therapeutics Major Business
- Table 61. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
- Table 62. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases
- Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 63. Amicus Therapeutics Recent Developments/Updates
- Table 64. Amicus Therapeutics Competitive Strengths & Weaknesses
- Table 65. Regenxbio Inc. Basic Information, Area Served and Competitors
- Table 66. Regenxbio Inc. Major Business
- Table 67. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product and Services
- Table 68. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Revenue,
- Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 69. Regenxbio Inc. Recent Developments/Updates



- Table 70. Regenxbio Inc. Competitive Strengths & Weaknesses
- Table 71. Sarepta Therapeutics Basic Information, Area Served and Competitors
- Table 72. Sarepta Therapeutics Major Business
- Table 73. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product and Services
- Table 74. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases
- Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 75. Sarepta Therapeutics Recent Developments/Updates
- Table 76. Sarepta Therapeutics Competitive Strengths & Weaknesses
- Table 77. Gensight Biologics Basic Information, Area Served and Competitors
- Table 78. Gensight Biologics Major Business
- Table 79. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product and Services
- Table 80. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Revenue,
- Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 81. Gensight Biologics Recent Developments/Updates
- Table 82. Gensight Biologics Competitive Strengths & Weaknesses
- Table 83. Krystal Biotech Basic Information, Area Served and Competitors
- Table 84. Krystal Biotech Major Business
- Table 85. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product and Services
- Table 86. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Revenue,
- Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 87. Krystal Biotech Recent Developments/Updates
- Table 88. Avexis Basic Information, Area Served and Competitors
- Table 89. Avexis Major Business
- Table 90. Avexis Gene Therapy for Neurodegenerative Diseases Product and Services
- Table 91. Avexis Gene Therapy for Neurodegenerative Diseases Revenue, Gross
- Margin and Market Share (2018-2023) & (USD Million)
- Table 92. Global Key Players of Gene Therapy for Neurodegenerative Diseases Upstream (Raw Materials)
- Table 93. Gene Therapy for Neurodegenerative Diseases Typical Customers List of Figure
- Figure 1. Gene Therapy for Neurodegenerative Diseases Picture
- Figure 2. World Gene Therapy for Neurodegenerative Diseases Total Market Size: 2018 & 2022 & 2029, (USD Million)
- Figure 3. World Gene Therapy for Neurodegenerative Diseases Total Market Size (2018-2029) & (USD Million)
- Figure 4. World Gene Therapy for Neurodegenerative Diseases Revenue Market Share



by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Figure 5. World Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Gene Therapy for Neurodegenerative Diseases Revenue (2018-2029) & (USD Million)

Figure 13. Gene Therapy for Neurodegenerative Diseases Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)

Figure 16. World Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)

Figure 18. China Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)

Figure 23. India Gene Therapy for Neurodegenerative Diseases Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Gene Therapy for Neurodegenerative Diseases by Player Revenue (\$MM) and Market Share (%): 2022



Figure 25. Global Four-firm Concentration Ratios (CR4) for Gene Therapy for Neurodegenerative Diseases Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Gene Therapy for Neurodegenerative Diseases Markets in 2022

Figure 27. United States VS China: Gene Therapy for Neurodegenerative Diseases Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Gene Therapy for Neurodegenerative Diseases Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Gene Therapy for Neurodegenerative Diseases Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type in 2022

Figure 31. Gene Replacement Therapy

Figure 32. Gene Silencing Therapy

Figure 33. Gene Editing Therapy

Figure 34. Enzyme Replacement Therapy

Figure 35. World Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Type (2018-2029)

Figure 36. World Gene Therapy for Neurodegenerative Diseases Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 37. World Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Application in 2022

Figure 38. Hospitals and Clinics

Figure 39. Research Institutions

Figure 40. Biotechnology Companies

Figure 41. Others

Figure 42. Gene Therapy for Neurodegenerative Diseases Industrial Chain

Figure 43. Methodology

Figure 44. Research Process and Data Source



I would like to order

Product name: Global Gene Therapy for Neurodegenerative Diseases Supply, Demand and Key

Producers, 2023-2029

Product link: https://marketpublishers.com/r/GC4760E854B7EN.html

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GC4760E854B7EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



